At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
T2345 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacokinetics, Efficacy and Safety Assessment of T2345 Compared With Active Comparator in Newly Diagnosed Patients With Open-angle Glaucoma or Ocular Hypertension
In Brief
A Phase 2 clinical trial evaluating T2345 and Prostaglandin for Primary Open Angle Glaucoma. Completed, enrolled 30 participants.
Detailed Summary
The purpose of this study is to assess the pharmacokinetics, efficacy and safety of T2345 versus an active comparator.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Open Angle Glaucoma
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2008
Primary CompletionDec 2008
First PostedDec 2011
TodayJul 2026
First PostedDec 19, 2011
Enrollment StartJun 1, 2008
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 14.5 years ago
Interventions
T2345drug
One drop at 8.00pm.
Prostaglandindrug
One drop at 8.00pm.